ZYLiQ Version 4.0: Transforming Regulatory Writing Automation
ZYLiQ Version 4.0: Transforming Regulatory Writing Automation
ZYLiQ, an innovator in AI and machine learning solutions specifically designed for regulatory medical writing, has introduced its latest product, ZYLiQ Version 4.0. This upgrade signifies a substantial leap towards enhancing automation efficiency in the realm of clinical study reporting (CSR) and introduces groundbreaking regulatory document modules.
As a leader in this unique industry space, ZYLiQ has earned acclaim for its ability to expedite CSR development by an impressive 75%. Such results are supported by a robust rate of customer renewals, which underscores the platform's innovation and its effectiveness in overcoming common regulatory writing hurdles.
Key Enhancements in ZYLiQ Version 4.0
One of the standout features of this latest version is its comprehensive suite of improvements directed at CSR automation.
Automatic Source-Type Prediction
Version 4.0 offers automatic source-type prediction for user-added sections. This enhancement allows users to focus on the content rather than the document structure, streamlining the overall writing process.
Optimized Content Creation
The software now enables optimized synopsis content creation. This feature enhances brevity and clarity, ensuring that essential points are highlighted while extraneous information is minimized.
GenAI-Powered Writing Assistances
Using cutting-edge GenAI technology, the platform provides tense conversion, streamlined writing, and in-text summary generation. This enhancement simplifies the drafting process, allowing for faster document assembly without sacrificing quality.
A New Era of Safety and Efficacy Drafting
Version 4.0 also equips users with AI-assisted drafting capabilities for Safety & Efficacy conclusion sections, ensuring that these critical components are addressed efficiently and thoroughly.
New Regulatory Modules Introduced
Along with the enhancements in CSR automation, ZYLiQ Version 4.0 introduces new modules tailored to various regulatory documents using Generative AI.
Automated Safety Narratives
A particularly noteworthy module focuses on Safety Narratives. It automatically extracts data from multiple sources, including listings and datasets, facilitating a 90% reduction in time to completion, as reported by its users. This swift capability revolutionizes the drafting of safety narratives.
Streamlined Informed Consent Form (ICF) Generation
The Informed Consent Form (ICF) generation module efficiently ingests protocol and investigator brochure content, guiding writers through an automated creation process that integrates sponsor-specific templates.
Plain Language Summaries
Versions 4.0 also simplifies the creation of Plain Language Summaries (PLS and PLPS) from CSR documents, ensuring that complex information is accessible to all audiences by converting technical language into layman’s terms.
Redaction and Anonymization Features
With heightened concern over data privacy, the redaction and anonymization feature allows users to mask or remove sensitive information seamlessly from any document, reinforcing compliance with regulatory requirements.
Zero-Risk Adoption with Free Pilot Offer
To demonstrate the capabilities of this advanced platform, ZYLiQ is offering potential customers a remarkable free two-week pilot. This opportunity allows users to compare their current legacy processes with the accelerated automation provided by ZYLiQ.
Farha Feroze, the inventor and Director of Product Management at ZYLiQ, expressed pride in the company's focus on regulatory document automation. She stated, "Our concentrated effort has empowered us to build an exceptionally effective solution. With Version 4.0, we are thrilled to extend our innovation to various regulatory documents. The progress made by my team in leveraging advanced technologies has been phenomenal."
About ZYLiQ
With an extensive background spanning three decades at contract research organization Symbiance, ZYLiQ stands as a frontrunner in life sciences. It merges unparalleled domain expertise with groundbreaking AI/ML innovations, rooted deeply in an understanding of customer challenges.
Contact ZYLiQ today to experience the future of regulatory writing technology. Get in touch with our team for more information on how we can support your regulatory writing needs.
Frequently Asked Questions
What improvements does ZYLiQ Version 4.0 offer?
ZYLiQ Version 4.0 enhances CSR automation and introduces new regulatory document modules aimed at boosting efficiency in regulatory writing.
How does ZYLiQ accelerate the CSR process?
The platform claims to expedite CSR development by up to 75%, improving the overall workflow for regulatory writing.
Can I try ZYLiQ before committing?
Yes, ZYLiQ offers a free two-week pilot to allow prospective customers to compare their existing processes with ZYLiQ's automation.
What new features are included in the latest version?
New features include automatic source-type prediction, AI-assisted drafting tools, and modules for generating safety narratives and Informed Consent Forms.
How can ZYLiQ support regulatory writing?
ZYLiQ addresses common challenges in regulatory writing by offering advanced AI solutions that streamline the creation and organization of necessary documents.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.